However, it remains to be formally investigated whether the activation of ferroptosis by FSP1 blockers may enable the orchestration of a tumor-specific immune response that can be further exacerbated by immune checkpoint inhibitors (ICIs). This evidence concerns the gene AIFM2 and neoplasm.